Involvement of Serotonergic System in Oxaliplatin-Induced Neuropathic Pain

Ji Hwan Lee and Woojin Kim *

Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02453, Korea; mibdna@khu.ac.kr
* Correspondence: wjkim@khu.ac.kr

Abstract: Oxaliplatin is a chemotherapeutic agent widely used against colorectal and breast cancers; however, it can also induce peripheral neuropathy that can rapidly occur even after a single infusion in up to 80–90% of treated patients. Numerous efforts have been made to understand the underlying mechanism and find an effective therapeutic agent that could diminish pain without damaging its anti-tumor effect. However, its mechanism is not yet clearly understood. The serotonergic system, as part of the descending pain inhibitory system, has been reported to be involved in different types of pain. The malfunction of serotonin (5-hydroxytryptamine; 5-HT) or its receptors has been associated with the development and maintenance of pain. However, its role in oxaliplatin-induced neuropathy has not been clearly elucidated. In this review, 16 in vivo studies focused on the role of the serotonergic system in oxaliplatin-induced neuropathic pain were analyzed. Five studies analyzed the involvement of 5-HT, while fourteen studies observed the role of its receptors in oxaliplatin-induced allodynia. The results show that 5-HT is not involved in the development of oxaliplatin-induced allodynia, but increasing the activity of the 5-HT1A, 5-HT2A, and 5-HT3 receptors and decreasing the action of 5-HT2C and 5-HT6 receptors may help inhibit pain.

Keywords: allodynia; chemotherapy-induced peripheral neuropathic pain; oxaliplatin; serotonin

1. Introduction

Oxaliplatin is a third-generation platinum-based chemotherapeutic drug widely used to treat various types of cancer [1–3]. Although it is effective against tumors, it can also induce side effects, such as mouth soreness, nausea, and vomiting, which may limit its use [4,5]. Among the various negative effects, the most prevalent is peripheral neuropathy, which is expressed as cold and mechanical allodynia in the feet and hands [6–8]. Dysesthesia and paresthesia can occur as early as 48 h after infusion [8]. Numerous studies have been conducted to understand the underlying mechanisms, and although it is yet clearly understood, malfunction of voltage-gated sodium channels [9] and organic cation transporters [10], mitochondrial dysfunction [11], oxidative stress [12], axonal degeneration [13], and impairment of the descending pain inhibitory system [14] have been proposed as the causes of this peripheral neuropathy.

Several groups of chemotherapy substances can cause peripheral neuropathy, such as platinum-based agents, taxanes, and immunomodulatory drugs; however, among them, platinum-based drugs are reported to cause the highest rate of peripheral neuropathy (70–100%) compared to other agents (e.g., taxanes and immunomodulatory drugs, 11–87% and 20–60%, respectively). Among the three platinum-based drugs (oxaliplatin, cisplatin, and carboplatin), acute neuropathy develops in approximately 65–98% of patients within hours of oxaliplatin infusion at a dose ranging from 85 to 130 mg/m², whereas cisplatin is induced in 92% of patients after cumulative treatment (500–600 mg/m²), and carboplatin is less toxic, as 13–42% of patients are induced [15–17]. These results showed that oxaliplatin could acutely induce neuropathic pain with higher rate compared to other platinum-based drugs.
For many years, our lab has focused on oxaliplatin-induced neuropathic pain, and continuous efforts have been made to understand its pathophysiology and to find an effective treatment that could reduce pain without affecting its anti-tumor effects [18–24]. Among many pathways, the serotonergic system in the central nervous system (CNS), which is part of the descending pain inhibitory system, has been shown to be deeply involved in oxaliplatin-induced neuropathic pain [25–29].

Serotonin (5-hydroxytryptamine; 5-HT) is a monoaminergic neurotransmitter synthesized from tryptophan via the sequential actions of tryptophan hydroxylase. In the CNS, it is produced primarily in the brainstem (rostral ventromedial medulla; RVM) [30], and in the peripheral nervous system (PNS), the main cellular sources of 5-HT are platelets and mast cells [31,32].

Synthesized 5-HT can interact with seven different families of 5-HT receptors that comprise 15 subtypes [30,33]. Among the seven classes, six are G-protein coupled receptors (5-HT1,2,4-7 receptors), whereas one is a ligand-gated cation channel (5-HT3 receptor) [34]. 5-HT and its receptors are widely known to be involved in pain attenuation [35,36], and enhancing 5-HT [37,38] or modulating the function of its receptor in the spinal cord has been reported to decrease pain in various animal models [35,39]. Among 5-HT receptor subtypes, 5-HT1A, 5-HT6 and 5-HT7 receptors are coupled to Gi/o, suggesting an inhibitory effect [40–43]. In contrast 5-HT2 receptor is coupled to Gq/11, and 5-HT3 receptor is directly linked to non-selective cationic channels, suggesting an excitatory effect [40,44,45]. However, their effect in pain is known to vary according to the types of pain and experimental conditions [35].

In our previous study [46], spinal mRNA expression of 5-HT1A receptors was downregulated 4 days after oxaliplatin injection, when pain behaviors were obvious, and it was upregulated when cold and mechanical allodynia were alleviated in mice. Moreover, intrathecal injection of 5-HT1A (NAN-190), 5-HT2A (ketanserin), or 5-HT3 (MDL-72222) receptor antagonists inhibited the analgesic effect of various treatments, suggesting that targeting the serotonergic system may be an effective method to modulate oxaliplatin-induced neuropathic pain [25,28].

Furthermore, although no agent has been recommended for prevention in the recently published guidelines from the American Society of Clinical Oncology (ASCO), duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has been recommended for the treatment of oxaliplatin-induced neuropathic pain [47]. Duloxetine has been reported to be effective in alleviating allodynia in several clinical trials [48,49], and although duloxetine is an SNRI, it is known to more potently block 5-HT than norepinephrine (NE) transporter, showing that 5-HT play an important role in the anti-allodynic effect of duloxetine [50]. In addition, in different animal models of neuropathic pain, fluoxetine, a selective serotonin reuptake inhibitors, significantly attenuate the pain, demonstrating the analgesic effect of 5-HT [51]. However, the underlying mechanism of action of serotonergic system is not yet clearly defined.

Therefore, clarifying the role of 5-HT in oxaliplatin-induced neuropathic pain is important not only to understand pain but also to develop optimal drugs. However, to date, no reviews have been published that summarize the involvement of the serotonergic system in oxaliplatin-induced neuropathic pain. In this review, by analyzing all studies that observed the involvement of 5-HT and its receptors, we will discuss the role of 5-HT and its receptors in oxaliplatin-induced peripheral neuropathic pain.

2. Results
2.1. Role of 5-HT in Oxaliplatin-Induced Neuropathic Pain

Five studies investigated the role of monoamine neurotransmitters in oxaliplatin-induced neuropathic pain (Table 1). Among many neurotransmitters, it is well accepted that 5-HT is involved in the pain modulation, although 5-HT is known to exert both pain facilitatory and inhibitory effect depending on the pain states and the type of receptors [32,35]. However, experimental studies reported that direct application of 5-HT into the spinal cord
generally inhibited nociceptive responses [52]. This may be due to the fact that 5-HT produce excitatory effect on many inhibitory neurons such as GABA (gamma-Aminobutyric acid) and glycine present in the spinal dorsal horn [39,53]. In this review, four studies conducted experiments by depleting 5-HT using PCPA [27–29,54], while one study directly measured the level of 5-HT in several areas of the brain [55]. PCPA is an irreversible inhibitor of tryptophan hydroxylase, which is used to synthesize 5-HT from tryptophan [56]. PCPA pretreatment is generally used to deplete 5-HT and has been reported to reduce central and peripheral 5-HT [57]. PCPA decreased the levels of 5-HT and its metabolite 5-hydroxyindoleacetic acid to 9.4% and 8.2% of control levels, respectively, in rats, without affecting the levels of norepinephrine and dopamine [58].

**Table 1. Involvement of 5-HT in oxaliplatin-induced neuropathic pain.**

| Authors                  | Strain     | Oxaliplatin | Treatments                          | Findings                                                                                                                                 |
|--------------------------|------------|-------------|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Masuguchi et al. (2014)  | SD rat     | 32 mg/kg, 8 times | Neurtropin (p.o., 50, 100, 200 NU/kg) | Depletion of 5-HT by PCPA (100 mg/kg, i.p.) did not affect the development of oxaliplatin-induced cold hyperalgesia and mechanical allodynia. Depletion of 5-HT abolished the analgesic effect of neurtropin (200 NU/kg) against both cold hyperalgesia and mechanical allodynia. |
| Lee et al. (2014)        | SD rat     | 6 mg/kg, single | BVA (s.c., 0.25 mg/kg)             | Depletion of 5-HT by PCPA (150 mg/kg, i.p.) did not affect the development of oxaliplatin-induced cold allodynia. Depletion of 5-HT completely abolished the analgesic effect of BVA against oxaliplatin-induced cold allodynia. Spinal 5-HT level was upregulated after BVA treatment, whereas PCPA inhibited its increase. |
| Hache et al. (2014)      | C57BL/6j   | 28 mg/kg, 4 times | Escitalopram (SSRI, s.c., 4 mg/kg), Venlafaxine (SNRI, s.c., 16 mg/kg), Indatraline (TRI, s.c., 3 mg/kg), NS18283 (TRI, s.c., 10 mg/kg) | Escitalopram, indatraline, and NS18283 suppressed mechanical allodynia induced by oxaliplatin. Venlafaxine, indatraline, and NS18283 showed significant efficacy in thermal preference test. Only indatraline increased latency on cold plate test. Extracellular 5-HT levels at ACC was significantly upregulated after escitalopram (215.7 ± 16.5% vs. 86.19 ± 7.0%), venlafaxine (283.8 ± 34.2% vs. 110.4 ± 3.4%), indatraline (194.6 ± 14.4% vs. 104.2 ± 8.03%), and NS18283 (196.0 ± 36.9% vs. 84.9 ± 11.6%) administration compared with vehicle treated group. |
| Li et al. (2015)         | SD rat     | 6 mg/kg, single | bvPLA2 (i.p., 0.2 mg/kg)            | Depletion of 5-HT by PCPA (150 mg/kg, i.p.) did not affect the development of oxaliplatin-induced cold and mechanical allodynia. Depletion of 5-HT failed to block the analgesic effect of bvPLA2 against oxaliplatin-induced allodynia. |
| Li et al. (2019)         | C57BL/6    | 6 mg/kg, single | Venlafaxine (SNRI, i.p., 10, 40, 60 mg/kg) | Depletion of 5-HT by PCPA (150 mg/kg, i.p.) did not affect the development of oxaliplatin-induced cold and mechanical allodynia. Venlafaxine attenuated oxaliplatin-induced cold and mechanical allodynia. Depletion of 5-HT abolished the analgesic effect of venlafaxine (40 mg/kg) on mechanical but not cold allodynia. |

**Abbreviations:** 5-HT; serotonin, ACC; anterior cingulate cortex, BVA; bee venom acupuncture, bvPLA2; bee venom phospholipase 2, i.p.; intraperitoneal, NU/kg; neurotropin units/kg, PCPA; para-chlorophenylalanine, p.o.; per os; s.c.; subcutaneous, SD rats; Sprague Dawley rats, SNRI; serotonin and norepinephrine reuptake inhibitor, SSRI; selective serotonin reuptake inhibitor, TRI; triple reuptake inhibitor.
Masuguchi et al. [54] reported that 5-HT depletion did not aggravate or prevent the development of cold and mechanical allodynia in rats. Three times intraperitoneal injection of PCPA significantly reduced the 5-HT content by 63% in the spinal cord (L1-L6, 519.1 ± 16.8 ng/g vs. 189.5 ± 22.2 ng/g), but oxaliplatin-induced neuropathic pain remained unaffected. However, depletion of 5-HT reduced the analgesic effect of neurotropin, as its analgesic effect was abolished after 5-HT depletion. Lee et al. [27] also used PCPA to deplete 5-HT in rats. PCPA was injected for 3 days and oxaliplatin was administered on the last day. Their results showed that PCPA depletion did not affect the development of oxaliplatin-induced cold allodynia. However, PCPA prevented the analgesic effect induced by subcutaneous injection of 0.25 mg/kg of bee venom acupuncture (BVA) at the GV3 acupuncture point. In their study, BVA administration significantly increased the level of 5-HT in the spinal cord, showing that increased 5-HT concentration resulted in oxaliplatin-induced pain attenuation. Similar to the results of Lee et al., Li et al. [29] also demonstrated that 5-HT depletion did not influence the development of cold and mechanical allodynia in mice. In their study, bee venom-derived phospholipase A2 (bvPLA2), which is one of the major subcomponents of BVA, demonstrated analgesic effects against both cold and mechanical allodynia even after PCPA injection, showing that the development and treatment were not affected by 5-HT. In a study by Li et al. [28], 5-HT depletion did not prevent or enhance pain development in mice; however, the analgesic effect of venlafaxine, an SNRI, on mechanical but not cold allodynia, was significantly blocked by pretreatment with PCPA.

Although Hache et al. [55] did not use PCPA to observe the effect of 5-HT on oxaliplatin-induced neuropathic pain, but they measured the 5-HT content in the anterior cingulate cortex (ACC) of mice before and after the administration of various monoamine reuptake inhibitors, such as SNRI, serotonin reuptake inhibitor, and triple reuptake inhibitors. ACC is an area of the brain known to be important for pain-related perception [59,60]. It receives dense 5-HT and norepinephrine innervation, and its descending projections are reported to be transmitted to RVM neurons [61]. Hache et al. conducted von Frey, cold plate, and thermal preference plate tests to assess its effect on oxaliplatin-induced mechanical, cold, and thermal allodynia. In the von Frey hair test, all drugs, except for venlafaxine, significantly decreased oxaliplatin-induced allodynia. In the cold plate test, only indatraline significantly increased the latency of the first jump compared to the control. In the thermal preference test, all drugs, but not escitalopram, were significantly effective. All four drugs significantly elevated the dose of 5-HT in ACC, but escitalopram and venlafaxine induced more extracellular 5-HT levels than norepinephrine, whereas indatraline and NS18283 increased norepinephrine levels compared to 5-HT.

### 2.2. Role of 5-HT Receptors in Oxaliplatin-Induced Neuropathic Pain

In total, 14 studies analyzed the involvement of 5-HT receptors in oxaliplatin-induced neuropathic pain. Nine studies focused on 5-HT$_1$ [26,27,46,54,62–66], six focused on 5-HT$_2$ [26,27,54,65,67,68], five on 5-HT$_3$ [25–28,54], and one study focused on 5-HT$_6$ [69] receptors. Most of the studies focused on the spinal cord, but two studies observed changes in the brain [67] and skin [63] (Table 2).
Table 2. The role of 5-HT receptors in oxaliplatin-induced neuropathic pain.

| Authors                       | Strain     | Oxaliplatin | Treatments                                                                 | Findings                                                                 |
|-------------------------------|------------|-------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Andoh et al. (2013) [62]      | C57BL/6NCr | 3 mg/kg,   | Xaliproden (Selective 5-HT1A receptor agonist, p.o., 0.3, 1, 3 mg/kg)       | Oxaliplatin mRNA of 5-HT1A R (DRG-, SC↑)                                   |
|                               | mouse      | i.p., single|                                                                            | Xaliproden Tibial nerve firing↓                                           |
| Masuguchi et al. (2014) [54]  | SD rat     | 32 mg/kg,  | Neurotropin (p.o., 50, 100, 200 NU/kg)                                      | 5-HT2A R (Ketanserin)                                                     |
|                               |            | i.p., 8 times|                                                                            | 5-HT3 R (MDL-72222)                                                       |
|                               |            |             |                                                                            | Antagonist (i.t.) Effect blocked                                           |
|                               |            |             |                                                                            | 5-HT1A R (WAY100635)                                                      |
|                               |            |             |                                                                            | antagonist (i.t.) Effect blocked (only cold allodynia)                     |
|                               |            |             |                                                                            | Pertussis toxin (Gi inhibitor, i.t.) Effect blocked                        |
| Baptista-de-Souza et al. (2014) [67] | SD rat | 36 mg/kg, i.p., 15 times | Fluoxetine (SSRI and 5-HT2C receptor antagonist, s.c., 20 mg/kg) | mRNA of 5-HT2C-R (SC and PAG↑, AMY↓, RVM-)                                |
|                               |            |             |                                                                            | Oxaliplatin Protein of 5-HT2C-R (SC and PAG↑, RVM, AMY-)                   |
|                               |            |             |                                                                            | mRNA of 5-HT2C-R (SC↓, AMY↑, RVM & PAG-)                                  |
|                               |            |             |                                                                            | Protein of 5-HT2C-R (SC↑, PAG and AMY↑, RVM-)                             |
| Authors                   | Strain          | Oxaliplatin | Treatments                                | Findings                  | Mechanisms                                                                 |
|--------------------------|-----------------|-------------|-------------------------------------------|---------------------------|-----------------------------------------------------------------------------|
| Lee et al. (2014)        | SD rat          | 6 mg/kg, i.p., single | BVA (s.c., 0.25 mg/kg)                    | Inhibit cold alldynia    | 5-HT_{1/2}R (Methysergide) 5-HT_{3}R (MDL-72222) antagonist (i.p.)          |
|                          |                 |             |                                           |                           | Effect blocked                                                            |
| Kim et al. (2016)        | C57BL/6 mouse   | 6 mg/kg, i.p., single | BVA and Morphine (s.c., 1 mg/kg and 2 mg/kg, respectively) | Inhibit cold and mechanical alldynia | 5-HT_{3}R (MDL-72222) antagonist (i.t.) Effect blocked                     |
| Lee et al. (2016)        | SD rat          | 6 mg/kg, i.p., single | EA (2 Hz, 20 min)                         | Inhibit cold alldynia    | 5-HT_{3}R (MDL-72222) antagonist (i.t.) Effect blocked                     |
| Andoh et al. (2016)      | C57BL/6NCr mouse | 3 mg/kg, i.p., single | Xaliproden or Tandospirone (5-HT_{1A} receptor agonist, p.o., 0.3, 1, 3 mg/kg) | Inhibit mechanical alldynia | Xaliproden Tandospirone Mast cell migration↓ (Plantar skin)               |
| Chenaf et al. (2017)     | SD rat          | 18 mg/kg, i.v., 9 times | Agomelatine (5-HT_{2C} receptor antagonist, i.p., 45 mg/kg) | Increase lowered TWL     | -                                                                          |
| Salat et al. (2017)      | CD-1 mouse      | 10 mg/kg, i.p., single | NLX-112 (5-HT_{1A} receptor agonist, i.p., 1.25, 2.5, 5 mg/kg) | Inhibit mechanical alldynia | -                                                                          |
Table 2. Cont.

| Authors                  | Strain   | Oxaliplatin       | Treatments                                                                 | Findings                                      | Mechanisms                                                                 |
|--------------------------|----------|-------------------|-----------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------------------------------------|
| Rapacz et al. (2018) [65]| CD-1 mouse | 10 mg/kg, i.p., single | 3,3-diphenyl-propionamides (JOA 122 (3p), i.p., 1, 10, 30 mg/kg)            | Inhibit mechanical allodynia                   | Binding affinity: 223.0 ± 4.5 nM $K_i$ ± SEM                              |
|                          |          |                   |                                                                             |                                               | 5-HT$_{1A}$R                                                                                |
|                          |          |                   |                                                                             |                                               | Binding affinity: >5000 nM $K_i$ ± SEM                                                    |
|                          |          |                   |                                                                             |                                               | 5-HT$_2A$R                                                                                |
|                          |          |                   |                                                                             |                                               | 5-HT$_2$R                                                                                 |
| Panczyk et al. (2018) [66]| CD-1 mouse | 10 mg/kg, i.p., single | 1-[3-(2,4,6-trimethylphenoxy)propyl]-4-(4-methoxyphenyl)piperazine dihydrochloride (Compound 3, 5-HT$_{1A}$ receptor antagonist, i.p., 30 mg/kg) | Fail to inhibit mechanical allodynia           | Binding affinity: 146.0 ± 28.4 nM $K_i$ ± SEM                                      |
|                          |          |                   |                                                                             |                                               | 5-HT$_{1A}$R antagonism                                                                     |
| Li et al. (2019) [28]   | C57BL/6 mouse | 6 mg/kg, i.p., single | Venlafaxine (SNRI, i.p., 10, 40, 60 mg/kg)                                  | Inhibit cold and mechanical allodynia          | 5-HT$_3$R (MDL-72222) antagonist (i.t.) Effect blocked                        |
|                         |          |                   |                                                                             |                                               | 5-HT$_{1/2}$R (Methysergide) antagonist (i.t.)                                             |
| Martin et al. (2020) [69]| SD rat   | 6 mg/kg, i.p., single | SB258585 (5-HT$_6$ receptor inverse agonist, i.p., 1, 5 µmol/kg)           | Inhibit cold and mechanical pain behaviors    | Tat-VEPE (reducing 5-HT$_6$R-mTOR interaction) Effect blocked                |
|                          |          |                   |                                                                             |                                               |                                                                                            |
| Lee et al. (2021) [46]  | C57BL/6 mouse | 6 mg/kg, i.p., single | Water extract of Z. officinale (p.o., 100, 300, 500 mg/kg)                 | Inhibit cold and mechanical allodynia          | Oxaliplatin mRNA of 5-HT$_{1A}$R (SC) Effect blocked                        |
|                          |          |                   |                                                                             |                                               | Z. officinale mRNA of 5-HT$_{1A}$R (SC)                                                      |

Abbreviations: 5-HT; serotonin, 5-HTR; serotonin receptor, AMY; amygdala, BVA; bee venom acupuncture, DRG; dorsal root ganglion, EA; electroacupuncture, i.v.; intravenous, i.p.; intraperitoneal, i.t.; intrathecal, mRNA; messenger RNA, NU/kg; neurotropin units/kg, PAG; periaqueductal gray, p.o.; per os, RVM; rostral ventromedial medulla, SC; spinal cord, SD rats; Sprague Dawley rats, SEM; standard error of the mean, SNRI; serotonin and noradrenaline reuptake inhibitor, SSRI; selective serotonin reuptake inhibitor, Tat-VEPE; fusion of sequence of amino acid (FFVTD5VEPE) to transduction domain of HIV Tat protein, TWL; tail withdrawal latency, Z. officinale; Zingiber officinale.
2.2.1. 5-HT\textsubscript{1} Receptors

Five different subtypes of 5-HT\textsubscript{1} receptors are present (5-HT\textsubscript{1A,B,D,E, and F})\cite{70}. Although the role of 5-HT\textsubscript{1D,E, and F} receptors in the pain state is poorly understood\cite{71}, 5-HT\textsubscript{1A} and B receptor agonists have been reported to reduce pain\cite{72}. In this study, all nine studies focused on 5-HT\textsubscript{1A} receptors; 5-HT\textsubscript{1A} receptors are involved in pain attenuation, since spinal 5-HT\textsubscript{1A} receptor stimulation using selective agonists resulted in analgesia in neuropathic animals\cite{73,74}. In the CNS, a large number of 5-HT\textsubscript{1A} receptors are present in serotonergic cells, mainly in the dorsal and median raphe nuclei\cite{35}. In the spinal cord, 5-HT\textsubscript{1A} receptors are known to be present in GABAergic interneurons located in the superficial and deeper layers of the spinal dorsal horn\cite{75}. In the PNS, they are expressed in capsaicin-sensitive C-fibers\cite{63,76}.

Andoh et al.\cite{62} reported that oxaliplatin produced mechanical allodynia from D7 to D14 and that the mRNA level of 5-HT\textsubscript{1A} receptors in the spinal dorsal horn, but not in the DRG, increased after a single injection of oxaliplatin. Although a single oral treatment with xaliproden, a selective 5-HT\textsubscript{1A} receptor agonist, failed to suppress oxaliplatin-induced mechanical allodynia, xaliproden partially suppressed the increase in tibial nerve firing after oxaliplatin treatment. The nerve firing was evoked with 0.69 mN of von Frey filament. However, this inhibition (32\%) was not significant enough to attenuate mechanical allodynia. In their study, xaliproden significantly attenuated mechanical allodynia induced by paclitaxel injection, which is another chemotherapeutic agent, and the nerve response decreased to 68\% compared to paclitaxel-treated mice. On the contrary to the study of Andoh et al., in a study by Lee et al.\cite{46} mRNA level of spinal 5-HT\textsubscript{1A} receptors was significantly downregulated after oxaliplatin treatment and upregulated when allodynic signs were alleviated. This discordance may be due to the difference in measurement time and the dose of oxaliplatin, as Andoh et al. observed 10 days after 3 mg/kg of oxaliplatin injection, while Lee et al. conducted experiments 5 days after 6 mg/kg of oxaliplatin. Due to the limited number of studies that observed the mRNA expression of 5-HT\textsubscript{1A} in the spinal cord after oxaliplatin treatment, it is hard to draw a firm conclusion; however, as in the spinal cord, 5-HT\textsubscript{1A} receptors are known to be expressed both in inhibitory interneurons and non-inhibitory interneurons\cite{77,78}, future study should be conducted to clarify which 5-HT\textsubscript{1A} receptors are upregulated or downregulated after oxaliplatin treatment.

In another study conducted by Andoh et al.\cite{63} daily oral treatment with selective 5-HT\textsubscript{1A} Receptor agonists (xaliproden or tandospirone) for 10 days significantly prevented the development of oxaliplatin-induced mechanical allodynia in mice. Moreover, treatment with selective 5-HT\textsubscript{1A} receptor agonists significantly reduced the number of mast cells in the plantar skin of mice. These results suggested that 5-HT\textsubscript{1A} receptor agonists may decrease oxaliplatin-induced mast cell migration by inhibiting the release of substance P from C-fiber afferent neurons. It should be noted that activation of the 5-HT\textsubscript{1A} receptor has been reported to cause hyperpolarization of capsaicin-sensitive neurons\cite{79,80}. Mast cells are known to participate in pain development by releasing inflammatory mediators such as ATP, histamine, and tryptase\cite{81}. Moreover, Sakamoto et al.\cite{82} have reported that oxaliplatin may activate C-fiber to release neuromodulators, which could degranulate mast cells. Subsequently, tryptase released from the mast cell can sensitize the A-fibers which could lead to allodynia.

According to the studies of Salat et al. and Rapacz et al.\cite{64,65}, intraperitoneal injection of NLX-112 and JOA 112 (3p), attenuated oxaliplatin-induced mechanical allodynia at the acute and late phase (3 h and 7 days after the injection of oxaliplatin, respectively). NLX-112 is a selective 5-HT\textsubscript{1A} receptor agonist, while JOA 112 (3p) has a moderate affinity for the 5-HT\textsubscript{1A} Receptors (K\textsubscript{i} ± SEM, 223.0 ± 4.5 nM). These results suggest that intraperitoneal injection of 5-HT\textsubscript{1A} receptor agonist may participate in the suppression of oxaliplatin-induced mechanical allodynia. In accordance with those results, Panczyk et al.\cite{66} reported that administration of 1-[3-(2,4,6-trimethylphenoxy)propyl]-4-(4-methoxyphenyl) piperazine dihydrochloride, which has the potency of a 5-HT\textsubscript{1A} receptor antagonist, did not show any significant analgesic effects against oxaliplatin-induced cold and mechanical allodynia.
Furthermore, by using a potent 5-HT\textsubscript{1A} antagonist WAY100635, Masuguchi et al. [54] reported that neurotropin (100 and 200 NU/kg) could significantly attenuate cold allodynia via the action of spinal 5-HT\textsubscript{1A} receptors, as WAY100635 pretreatment blocked the effect of neurotropin against cold allodynia.

Another potent 5-HT\textsubscript{1A} receptor antagonist (NAN-190) was used in two other studies conducted with BVA [27] and electroacupuncture (EA) [26]. In their experiments, intrathecal injection of 5-HT\textsubscript{1A} receptor antagonist failed to inhibit the anti-allodynic effect of BVA and EA administered at Yaoyangguan (GV3) and Zusanli (ST36) acupuncture point, respectively, indicating that the effect of BVA and EA was not mediated by spinal 5-HT\textsubscript{1A} receptors. However, although intrathecal treatment of 5-HT\textsubscript{1A} receptors antagonist failed to inhibit the effect of BVA, when mixed 5-HT\textsubscript{1/2} antagonists (methysergide) was pretreated intraperitoneally the effect of BVA was blocked showing that the effect of BVA may be mostly mediated by peripheral 5-HT\textsubscript{1} or 5-HT\textsubscript{2} receptors than 5-HT\textsubscript{1A} receptors in the spinal cord.

2.2.2. 5-HT\textsubscript{2} Receptors

The 5-HT\textsubscript{2} receptors are G-protein coupled receptors, with three subtypes, 5-HT\textsubscript{2A}, 5-HT\textsubscript{2B}, and 5-HT\textsubscript{2C}. Compared to 5-HT\textsubscript{1} receptors, 5-HT\textsubscript{2} receptors are present in the spinal cord with relatively low density [83], and they are primarily reported to be found in the ventral than in the dorsal horn of the spinal cord [84]. The 5-HT\textsubscript{2A} and 5-HT\textsubscript{2C} receptors have a widespread distribution and function in the CNS, whereas 5-HT\textsubscript{2B} receptors have restricted expression [85]. In the included studies, the roles of 5-HT\textsubscript{2A} and 5-HT\textsubscript{2C} receptors were observed.

The involvement of 5-HT\textsubscript{2A} receptors in cold and mechanical allodynia has been assessed by Masuguchi et al. [54]. Intrathecal administration of 5-HT\textsubscript{2A} receptor antagonists (ketanserin) significantly inhibited the effect of neurotropin on cold hyperalgesia and mechanical allodynia, suggesting that spinal 5-HT\textsubscript{2A} receptor activation may lead to oxaliplatin-induced neuropathic pain attenuation. However, in the studies by Lee et al. [27] and Lee et al. [26] 5-HT\textsubscript{2A} receptor antagonists (ketanserin) failed to block the analgesic effect of BVA and EA, demonstrating that 5-HT\textsubscript{2A} receptors are not involved in their pain-alleviating pathways.

Although in this review, only one study demonstrated the involvement of 5-HT\textsubscript{2A} receptors in oxaliplatin-induced allodynia, the pain suppression effect of 5-HT\textsubscript{2A} receptors has been reported in different types of pain. In a mono-arthritis animal model of pain, upregulated mRNA expression of 5-HT\textsubscript{2A} receptors was observed in the nucleus of the RVM, ventrolateral periaqueductal gray, and spinal cord when the pain was attenuated [86]. Moreover, in an animal model of diabetes- and traumatic-induced neuropathic pain, increase in 5-HT\textsubscript{2A} receptors responsiveness resulted to pain inhibition [87,88]. In addition, in nerve injury-induced mechanical and thermal hyperalgesia, the activation of spinal 5-HT\textsubscript{2A} receptor-induced upregulation of potassium chloride co-transporter type 2 (KCC2) and suppressed pain [89].

Baptista-de-Souza et al. [67] analyzed the mRNA and protein expression of 5-HT\textsubscript{2C} receptors in the spinal cord, periaqueductal gray (PAG), and amygdala (AMY) after oxaliplatin and fluoxetine administration. Oxaliplatin administration induced mechanical and cold allodynia in rats and upregulated the mRNA and protein expression of 5-HT\textsubscript{2C} receptors in the spinal cord and PAG but was downregulated in AMY. Multiple subcutaneous injections of fluoxetine, which acts as a competitive 5-HT\textsubscript{2C} receptor antagonist, decreased mechanical and cold allodynia induced by oxaliplatin. Moreover, it decreased the mRNA and protein levels of 5-HT\textsubscript{2C} receptors in the spinal cord, while in the AMY, they were increased. In PAG, only the protein, but not the mRNA level, was upregulated. In a surgical paw incision pain model rodents, blocking the spinal 5-HT\textsubscript{2C} receptor prevented the hyperactivity of spinal neuron [90]. Furthermore, activation of 5-HT\textsubscript{2C} receptors in the AMY has been reported to enhance fear-induced antinociception in rats [91]. Also, activation of 5-HT\textsubscript{2C} receptors present in the PAG was demonstrated to increases antinoci-
ception in mice exposed to the elevated plus-maze [92]. Altogether, these result support that decreasing the activity of spinal 5-HT\textsubscript{2C} receptors in the spinal cord, and increasing the function of 5-HT\textsubscript{2C} receptors in the AMY and PAG could result in pain reduction.

Chenaf et al. [68] also demonstrated that intraperitoneal treatment with agomelatine, a 5-HT\textsubscript{2C} receptor antagonist, significantly suppressed oxaliplatin-induced cold allodynia at 45 min and 24 h after injection. These results suggest that both 5-HT\textsubscript{2A} receptor agonists and 5-HT\textsubscript{2C} receptor antagonists could attenuate oxaliplatin-induced neuropathic pain.

2.2.3. 5-HT\textsubscript{3} Receptors

Among all 5-HT receptor families, 5-HT\textsubscript{3} receptors are the only non-selective ligand-gated ion channels [93]. In the PNS, they are localized in the DRG and in the myelinated and unmyelinated primary afferent fiber terminals [94]. As ligand-gated ion channels, activation of 5-HT\textsubscript{3} receptors in DRG has been shown to induce pronociceptive effects [95,96]. However, in the spinal cord, they are mostly found in the superficial laminae and inhibitory GABAergic interneurons showing antinociceptive effects [35].

Five studies have observed the role of spinal 5-HT\textsubscript{3} receptors in the analgesic effect on oxaliplatin-induced pain. Although different treatment methods have been applied in each study, they all reported that intrathecal pretreatment with a 5-HT\textsubscript{3} receptor antagonist (MDL-72222) significantly blocked the analgesic effect. Masuguchi et al. [54] reported that the effect of neurotropin was inhibited by a 5-HT\textsubscript{3} receptor antagonist. Lee et al. [27] and Kim et al. [25] showed that the anti-allodynic effect of BVA alone or with morphine was blocked by MDL-72222 pretreatment. Lee et al. [26] and Li et al. [28] also reported that the effects of EA and venlafaxine were blocked by a 5-HT\textsubscript{3} receptor antagonist. These results show that intrathecal administration of 5-HT\textsubscript{3} receptor agonists may be an effective agent for treating oxaliplatin-induced neuropathic pain.

2.2.4. 5-HT\textsubscript{6} Receptors

5-HT\textsubscript{6} receptors are one of the most recently added receptors to the 5-HT family [97]. They are expressed in the excitatory interneurons of the spinal cord dorsal horn [33]. In an animal model of spinal nerve injury, 5-HT\textsubscript{6} receptor antagonists significantly blocked allodynia [98], and in the rat formalin test, both spinal and peripheral 5-HT\textsubscript{6} receptors played a pronociceptive role [99].

Martin et al. [69] observed the effect of the 5-HT\textsubscript{6} receptor inverse agonist and antagonist, SB258585 and PZ-1388, respectively, on oxaliplatin-induced cold and mechanical pain behavior. Both drugs significantly attenuated oxaliplatin-induced pain behavior. Furthermore, injection of an interfering peptide (Tat-VEPE), which looses the interaction between the 5-HT\textsubscript{6} receptor and mTOR, attenuates oxaliplatin-induced cold and mechanical allodynia. Notably, 5-HT\textsubscript{6} receptors are known to engage in mTOR signaling, which is reported to be involved in the modulation of neuropathic pain [100].

3. Discussion

In this review, 16 animal studies focused on the serotonergic system in oxaliplatin-induced neuropathic pain were analyzed. Five studies [27–29,54,55] focused on the role of 5-HT, while fourteen studies observed the role of its receptors in oxaliplatin-induced allodynia. Three studies discussed both 5-HT and its receptors [27,28,54]. To our knowledge, this is the first review that focuses on the involvement of the serotonergic system in oxaliplatin-induced neuropathic pain. As part of the descending pain inhibitory system, the serotonergic system has long been known to play an active role in various types of pain [35,36,101,102]. However, its role in oxaliplatin-induced neuropathic pain has not been clearly defined.

Among the included studies, four studies pretreated PCPA to observe the role of 5-HT in oxaliplatin-induced allodynia in rodents. Their results showed that 5-HT may not be involved in the development of neuropathic pain, as 5-HT depletion did not aggravate or attenuate oxaliplatin-induced neuropathic pain [26,28,29,54]. In contrast, 5-HT important
in mediating the analgesic effect, as some drugs did not alleviate allodynia when 5-HT was depleted [27,28,54]. These results are consistent with the guidelines of ASCO as SNRI, which increases the level of monoamine neurotransmitters, has been recommended only for treatment but not for prevention of chemotherapy-induced neuropathic pain [47]. Furthermore, these results also suggest that the impairment of 5-HT in the descending pain inhibitory system may not be the leading cause of oxaliplatin-induced pain. Oxaliplatin may be more focused on altering the function of neurons in the periphery (e.g., altering the function of Na⁺ channels [9]) than in the brain or the spinal cord, as it has limited permeability to the BBB [103,104]. Thus, 5-HT concentration in the CNS and PNS may not affect the development of pain; however, 5-HT could decrease pain by modulating pain signal transmission through the action of its receptors present in the brain, spinal cord, and peripheral nerves (Figure 1). In line with this, noradrenaline depletion [28] or silencing the locus coeruleus region [105] where most of the descending noradrenergic system originate did not aggravate the oxaliplatin-induced neuropathic pain showing that both 5-HT and noradrenaline depletion does not affect the development of neuropathic pain. These results suggest that attenuating the 5-HT and noradrenergic system does not affect; however, increasing the tone of noradrenaline and 5-HT may affect the development of pain.

To observe the role of 5-HT₁A receptors, various types of 5-HT₁A receptor agonists have been administered. Xaliproden, a selective 5-HT₁A receptor agonist, did not attenuate oxaliplatin-induced mechanical allodynia when administered orally; however, its multiple administrations significantly reduced pain. Xaliproden was administered for 10 consecutive days and the pain alleviating effect initiated on D3 and peaked at D10 [63]. These results show that single treatment may not be sufficient to attenuate oxaliplatin-induced neuropathic pain. Although conducted in different animal model of disease, single administration of 5-HT₁A receptors resulted in acute decrease of 5-HT level in the brain area, whereas chronic treatment for 21 days resulted in increase of 5-HT synthesis [106], this may partially explain why multiple, but not single treatment succeeded to alleviated allodynia.

Intraperitoneal injection of NLX-112, which is reported to have full agonist activity against 5-HT₁A receptors, also decreased mechanical allodynia. Tandospirone is known to be a highly potent partial agonist of 5-HT₁A receptors, as it has a Kᵢ value of 27 ± 5 nM [107], and its multiple treatments significantly attenuated pain such as xaliproden. Moreover, JOA 122 (3p), which has a moderate affinity with a Kᵢ value of 223.0 ± 4.5 nM, decreased

---

**Figure 1.** The involvement of spinal serotonergic receptors in the alleviation of oxaliplatin-induced neuropathic pain. Oxaliplatin administration increases the transmission of nociceptive signals from the primary afferent fibers to the brain (red). Activation of spinal 5-HT₁A, 2A, and 3 receptors and inhibition of spinal 5-HT₂C and 6 receptors could reduce allodynia induced by oxaliplatin (blue). 5-HT₁R, 5-HT receptors.

---
the acute and late phases of oxaliplatin-induced neuropathic pain. However, the 5-HT$_{1A}$ receptor antagonist (compound 3), with a $K_i$ value of 146.0 ± 28.4 nM, did not affect oxaliplatin-induced neuropathy. These results suggest that therapeutic agents that could stimulate both spinal and peripheral 5-HT$_{1A}$ receptors can effectively alleviate oxaliplatin-induced neuropathic pain.

In contrast to 5-HT$_{1A}$ receptors, Baptista-de-Souza et al. [67] and Chenaf et al. [68] demonstrated that inhibiting the action of 5-HT$_{2C}$ receptors could attenuate pain. In a study by Baptista-de-souza, multiple injections of oxaliplatin significantly increased the mRNA levels of 5-HT$_{2C}$ receptors in the spinal cord and PAG, and the selective 5-HT$_{2C}$ receptor antagonist fluoxetine decreased the increased level of 5-HT$_{2C}$ receptors in the spinal cord, but not in the PAG. In contrast to the results of Baptista-de-Souza and Chenaf, some studies have reported that intrathecal administration of various 5-HT$_{2C}$ receptor agonists such as 6-chloro-2-(1-piperazinyl)-pyrazine, 1-(m-chlorophenyl)-piperazine, or 1-(m-trifluoromethylphenyl)-piperazine could significantly decrease neuropathic pain in rodents [108–110]. These results suggest that the role of spinal 5-HT$_{2C}$ receptors may differ between pain models (i.e., spinal cord injury [SCI] vs. oxaliplatin). In addition, it should also be considered that the route of administration was different (intrathecal vs. intravenous and subcutaneous). Further studies that directly inject 5-HT$_{2C}$ receptor agonists or antagonists into the spinal cord of oxaliplatin-induced pain rats need to be conducted to clarify the role of spinal 5-HT$_{2C}$ receptors.

In contrast to 5-HT$_{2C}$ receptors, activation of 5-HT$_{2A}$ receptors was shown to alleviate pain, as spinal 5-HT$_{2A}$ receptor antagonist pretreatment significantly blocked the analgesic effect of neurotropin. Taken together, these results demonstrate that 5-HT$_{2A}$ receptors promote antinociception, whereas 5-HT$_{2C}$ receptors play a pain-enhancing role in oxaliplatin-induced pain. Although future studies are needed to clarify the role of 5-HT$_{2A}$ and 5-HT$_{2C}$ receptor in oxaliplatin-induced pain, the function of these receptors may be different as 5-HT$_{2A}$ receptors are known to be expressed in spinal inhibitory interneurons and have an antinociceptive role [111,112], whereas the activation of spinal 5-HT$_{2C}$ receptors were reported to excites neurons [113–115], and its distribution in the spinal cord was demonstrated to be compatible with a pronociceptive role of 5-HT in the dorsal horn [116].

Furthermore, published reports of included studies suggested that spinal 5-HT$_{3}$ receptors are involved in the attenuation of oxaliplatin-induced neuropathic pain. 5-HT$_{3}$ receptors are known to be present in the superficial laminae of the spinal dorsal horn at the terminals of myelinated and unmyelinated primary afferent fibers. As mentioned previously, they are also known to mediate the release of GABA, but not glycine or glutamate [117,118]. In contrast to the analgesic role in oxaliplatin-induced neuropathy, in humans suffering from chronic neuropathic pain and SCI-induced neuropathic pain model mice, treatment with ondansetron, a 5-HT$_{3}$ receptor antagonist, has been reported to produce a robust and long-term reduction in allodynia [119,120]. However, in our review, no studies have reported changes in behavioral response following administration of the 5-HT$_{3}$ receptor antagonist. Although it is difficult to clarify the reasons for this inconsistency, it may be due to differences in the antagonists used (ondansetron vs. MDL-72222). It should be noted that ondansetron, along with its 5-HT$_{3}$ receptor antagonistic effects, has been reported to act as a local anesthetic by blocking sodium channels [121,122].

In conclusion, our review demonstrates that 5-HT is not involved in the development of oxaliplatin-induced allodynia, but modulation of 5-HT may help attenuate allodynia. Furthermore, the results suggest that increasing the activity of the spinal 5-HT$_{1A}$, 5-HT$_{2A}$, and 5-HT$_{3}$ receptors and decreasing the action of the spinal 5-HT$_{2C}$ and 5-HT$_{6}$ receptors may help to inhibit pain. However, more constructively designed experiments that use receptor knockout and selective agonists and antagonists should be conducted to deduce any firm conclusions. Considering that oxaliplatin is one of the most widely used anti-cancer agents and no optimal treatment for oxaliplatin-induced pain exists, our efforts to clarify the role of the serotonergic system may help other researchers to find an optimal drug to alleviate the suffering of patients with chemotherapy-induced peripheral neuropathic pain.
Author Contributions: Conceptualization, W.K.; writing—original draft preparation, J.H.L. and W.K.; writing—review and editing, J.H.L. and W.K. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2020R1A5A2019413).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Graham, J.; Muhsin, M.; Kirkpatrick, P. Oxaliplatin. Nat. Rev. Drug Discov. 2004, 3, 11. [CrossRef] [PubMed]
2. Watanabe, T.; Kobunai, T.; Yamamoto, Y.; Matsuda, K.; Ishihara, S.; Nozawa, K.; Inumasa, H.; Konishi, T.; Horie, H.; Ikeuchi, H. Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. Clin. Transl. Oncol. 2011, 13, 419–425. [CrossRef] [PubMed]
3. Bleiberg, H. Oxaliplatin (L-OHP): A new reality in colorectal cancer. Br. J. Cancer 1998, 77, 1–3. [CrossRef] [PubMed]
4. Cassidy, J.; Misset, J.-L. Oxaliplatin-related side effects: Characteristics and management. Semin. Oncol. 2002, 29, 11–20. [CrossRef]
5. Grothey, A. Oxaliplatin-safety profile: Neurotoxicity. Semin. Oncol. 2003, 30, 5–13. [CrossRef]
6. Kidwell, K.M.; Yothers, G.; Ganz, P.A.; Land, S.R.; Ko, C.Y.; Ceccini, R.S.; Kopec, J.A.; Wolmark, N. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 2012, 118, 5614–5622. [CrossRef]
7. Cersosimo, R.J. Oxaliplatin-associated neuropathy: A review. Ann. Pharmacother. 2005, 39, 128–135. [CrossRef]
8. Lehky, T.; Leonard, G.; Wilson, R.; Grem, J.; Floeter, M. Oxaliplatin-induced neurotoxicity: Acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29, 387–392. [CrossRef]
9. Waseem, M.; Kaushik, P.; Tabassum, H.; Parvez, S. Role of mitochondrial mechanism in chemotherapy-induced peripheral neuropathy. Curr. Drug Metab. 2018, 19, 47–54. [CrossRef] [PubMed]
10. Mannelli, L.D.C.; Zanardelli, M.; Failli, P.; Ghelardini, C. Oxaliplatin-induced neuropathy: Oxidative stress as pathological mechanism. Protective effect of silibinin. J. Pain 2012, 13, 276–284. [CrossRef]
11. Meregalli, C.; Fumagalli, G.; Alberti, P.; Canta, A.; Chiorazzi, A.; Monza, L.; Pozzi, E.; Carozzi, V.A.; Blennow, K.; Zetterberg, H. Neurofilament light chain: A specific serum biomarker of axonal damage severity in rat models of Chemotherapy-Induced Peripheral Neurotoxicity. Arch. Toxicol. 2020, 94, 2517–2522. [CrossRef] [PubMed]
12. Norcini, M.; Vivoli, E.; Galeotti, N.; Bianchi, E.; Bartolini, A.; Ghelardini, C. Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat. Pain 2009, 146, 141–157. [CrossRef] [PubMed]
13. Banach, M.; Juranek, J.K.; Zyrgulis, A.L. Chemotherapy-induced neuropathies—A growing problem for patients and health care providers. Brain Behav. 2017, 7, e00558. [CrossRef]
14. Seretny, M.; Currie, G.L.; Sena, E.S.; Ramnarine, S.; Grant, R.; MacLeod, M.R.; Colvin, L.A.; Fallon, M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014, 155, 2461–2470. [CrossRef]
15. Zajczewska, R.; Kocot-Kępska, M.; Leppert, W.; Wrzosek, A.; Mika, J.; Wordliczek, J. Mechanisms of chemotherapy-induced peripheral neuropathy. Int. J. Mol. Sci. 2019, 20, 1451. [CrossRef]
16. Lee, J.H.; Kim, W. The role of satellite glial cells, astrocytes, and microglia in oxaliplatin-induced neuropathic pain. Biomedicines 2020, 8, 324. [CrossRef]
17. Lee, J.H.; Gang, J.; Yang, E.; Kim, W.; Jin, Y.H. Bee Venom Acupuncture Attenuates Oxaliplatin-Induced Neuropathic Pain by Modulating Action Potential Threshold in A-Fiber Dorsal Root Ganglia Neurons. Toxins 2020, 12, 737. [CrossRef]
18. Choi, S.; Yamada, A.; Kim, W.; Kim, S.K.; Furue, H. Noradrenergic inhibition of spinal hyperexcitability elicited by cutaneous cold stimuli in rats with oxaliplatin-induced allodynia: Electrophysiological and behavioral assessments. J. Physiol. Sci. 2017, 67, 431–438. [CrossRef]
19. Kim, C.; Lee, J.H.; Kim, W.; Li, D.; Kim, Y.; Lee, K.; Kim, S.K. The suppressive effects of Cinnamomi Cortex and its phytochemical coumarin on oxaliplatin-induced neuropathic cold allodynia in rats. Molecules 2016, 21, 1253. [CrossRef] [PubMed]
20. Kim, W.; Chung, Y.; Choi, S.; Min, B.I.; Kim, S.K. Duloxetine protects against oxaliplatin-induced neuropathic pain and spinal neuron hyperexcitability in rodents. Int. J. Mol. Sci. 2017, 18, 2626. [CrossRef] [PubMed]
21. Chae, H.K.; Kim, W.; Kim, S.K. Phytochemicals of cinnamonom cortex: Cinnamic acid, but not cinnamaldehyde, attenuates oxaliplatin-induced cold and mechanical hypersensitivity in rats. Nutrients 2019, 11, 432. [CrossRef]
22. Jung, Y.; Lee, J.H.; Kim, W.; Yoon, S.H.; Kim, S.K. Anti-allodynic effect of Buja in a rat model of oxaliplatin-induced peripheral neuropathy via spinal astrocytes and pro-inflammatory cytokines suppression. BMC Complement. Altern. Med. 2017, 17, 1–8. [CrossRef] [PubMed]
23. Kim, W.; Kim, M.J.; Go, D.; Min, B.I.; Na, H.S.; Kim, S.K. Combined Effects of Bee Venom Acupuncture and Morphine on Oxaliplatin-Induced Neuropathic Pain in Mice. Toxins 2016, 8, 33. [CrossRef]
26. Lee, J.H.; Go, D.; Kim, W.; Lee, G.; Bae, H.; Quan, F.S.; Kim, S.K. Involvement of spinal muscarinic and serotoninergic receptors in the anti-allodynic effect of electroacupuncture in rats with oxaliplatin-induced neuropathic pain. *Korean J. Physiol. Pharm.* 2016, 20, 407–414. [CrossRef] [PubMed]

27. Lee, J.H.; Li, D.X.; Yoon, H.; Go, D.; Quan, F.S.; Min, B.I.; Kim, S.K. Serotonergic mechanism of the relieving effect of bee venom acupuncture on oxaliplatin-induced neuropathic cold allodynia in rats. *BMC Complement. Altern. Med.* 2014, 14, 471. [CrossRef]

28. Li, D.; Lee, J.H.; Choi, C.W.; Kim, J.; Kim, S.K.; Kim, W. The Analgesic Effect of Venlafaxine and Its Mechanism on Oxaliplatin-Induced Neuropathic Pain in Mice. *Int. J. Mol. Sci.* 2019, 20, 1652. [CrossRef]

29. Li, D.; Lee, Y.; Kim, W.; Lee, K.; Bae, H.; Kim, S.K. Analgesic Effects of Bee Venom Derived Phospholipase A2 in a Mouse Model of Oxaliplatin-Induced Neuropathic Pain. *Toxins* 2015, 7, 2422–2434. [CrossRef] [PubMed]

30. Barnes, N.M.; Sharp, T. A review of central 5-HT receptors and their function. *Neuropharmacology* 1999, 38, 1083–1152. [CrossRef]

31. Namkung, J.; Kim, H.; Park, S. Peripheral serotonin: A new player in systemic energy homeostasis. *Mol. Cells* 2015, 38, 1023. [PubMed]

32. Sommer, C. Serotonin in pain and pain control. In *Handbook of Behavioral Neuroscience*; Elsevier: Amsterdam, The Netherlands, 2010; Volume 21, pp. 457–471.

33. Abraira, V.E.; Kuehn, E.D.; Chirila, A.M.; Springel, M.W.; Toliver, A.A.; Zimmerman, A.L.; Orefice, L.L.; Boyle, K.A.; Bai, L.; Song, B.J. The cellular and synaptic architecture of the mechanosensory dorsal horn. *Cell* 2017, 168, 295–310.e19. [CrossRef] [PubMed]

34. Nichols, D.E.; Nichols, C.D. Serotonin receptors. *Chem. Rev.* 2008, 108, 1614–1641. [CrossRef]

35. Bardin, L. The complex role of serotonin and 5-HT receptors in chronic pain. *Chem. Rev.* 2008, 108, 1614–1641. [CrossRef]

36. Millan, M.J. Descending control of pain. *Behav. Pharmacol.* 2002, 66, 355–474. [CrossRef]

37. Jordan, L.; Kenshalo, D., Jr.; Martin, R.; Haber, L.; Willis, W. Depression of primate spinothalamic tract neurons by iontophoretic application of 5-hydroxytryptamine. *Pain* 1978, 5, 135–142. [CrossRef]

38. Seyrek, M.; Kahraman, S.; Deveci, M.S.; Yesilyurt, O.; Dogrul, A. Systemic cannabinoids produce CB1-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT7 and 5-HT2A receptors. *Eur. J. Pharmacol.* 2015, 778, 165–173. [CrossRef]

39. Megumu, Y.; Hidemasa, F. Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotoninergic systems in the spinal cord. *J. Pharmacol. Sci.* 2006, 101, 107–117.

40. Abe, K.; Kato, G.; Katafuchi, T.; Tamae, A.; Furue, H.; Yoshimura, M. Responses to 5-HT in morphologically identified neurons in the rat substantia gelatinosa in vitro. *Neuroscience* 2009, 159, 316–324. [CrossRef]

41. Ito, A.; Kumamoto, E.; Takeda, M.; Takeda, M.; Shibata, K.; Sagai, H.; Yoshimura, M. Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: Participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord. *J. Neurosci.* 2000, 20, 6302–6308. [CrossRef]

42. Seyrek, M.; Kahraman, S.; Deveci, M.S.; Yesilyurt, O.; Dogrul, A. Systemic cannabinoids produce CB1-mediated antinociception by activation of descending serotonergic pathways that act upon spinal 5-HT7 and 5-HT2A receptors. *Eur. J. Pharmacol.* 2015, 778, 165–173. [CrossRef]

43. Leynartes, O.; Dogrul, A.; Yildirim, V.; Sahin, A.; Sizlan, A.; Seyrek, M.; Akgul, O.; Kozak, O.; Kurt, E.; Aypar, U. Spinal 5-HT7 receptors play an important role in the antinociceptive and anti-hyperalgesic effects of tramadol and its metabolite, O-Desmethyltramadol, via activation of descending serotonergic pathways. *J. Am. Soc. Anesthesiol.* 2010, 112, 696–710. [CrossRef] [PubMed]

44. Fukushima, T.; Ohstsubo, T.; Tsuda, M.; Yanagawa, Y.; Hori, Y. Facilitatory actions of serotonin type 3 receptors on GABAergic inhibitory synaptic transmission in the spinal superficial dorsal horn. *J. Neurophysiol.* 2009, 102, 1459–1471. [CrossRef]

45. Sasaki, M.; Ohata, S.; Saito, G.; Futo, T. Antinociception with intrathecal α-methyl-5-hydroxytryptamine, a 5-hydroxytryptamine 2A/2C receptor agonist, in two rat models of sustained pain. *Anesth. Analg.* 2003, 96, 1072–1078. [CrossRef] [PubMed]

46. Lee, J.H.; Min, D.; Lee, D.; Kim, W. Zingiber officinale Roscoe Rhizomes Attenuate Oxaliplatin-Induced Neuropathic Pain in Mice. *Molecules* 2021, 26, 548. [CrossRef] [PubMed]

47. Loprinzi, C.L.; Lacchetti, C.; Bleeker, J.; Cavaletti, G.; Chauhan, C.; Hertz, D.L.; Kelley, M.R.; Lavino, A.; Lustberg, M.B.; Paice, J.A. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update. *J. Clin. Oncol.* 2020, 38, 3325–3348. [CrossRef]

48. Yang, Y.-H.; Lin, J.-K.; Chen, W.-S.; Lin, T.-C.; Yang, S.-H.; Jiang, J.-K.; Chang, S.-C.; Lan, Y.-T.; Lin, C.-C.; Yen, C.-C. Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: An open-label pilot study. *Supportive Care Cancer* 2012, 20, 1491–1497. [CrossRef]

49. Chi, J.; Fayezy, F.; Chung, S.Y.; Jose, J.; Komorowski, A.W.; Dillon, M.; Shepherd, P.; Gold, K.D.; Saif, W.M. Duloxetine (DL) in treatment of oxaliplatin-induced peripheral neuropathy (PN). *Am. Soc. Clin. Oncol. Oncl.* 2021, 39, 195. [CrossRef]

50. Stahl, S.M.; Grady, M.M.; Moret, C.; Briley, M. SNRIs: The pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. *CNS Spectr.* 2005, 10, 732–747. [CrossRef]

51. Pedersen, L.H.; Nielsen, A.N.; Blackburn-Munro, G. Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. *Psychopharmacology* 2005, 182, 551–561. [CrossRef]

52. El-Yasser, N.; Fleetwood-Walker, S. A 5-HT1-type receptor mediates the antinociceptive effect of nucleus raphe magnus stimulation in the rat. *Brain Res.* 1990, 523, 92–99. [CrossRef]
53. Peng, Y.B.; Lin, Q.; Willis, W.D. The role of 5-HT3 receptors in periaqueductual gray-induced inhibition of nociceptive dorsal horn neurons in rats. J. Pharmacol. Exp. Ther. 1996, 276, 116–124. [PubMed]
54. Masaguchi, K.; Watanabe, H.; Kawashiri, T.; Usibio, S.; Ozawa, N.; Morita, H.; Oishi, R.; Egashira, N. Neurotropin(R) relieves oxiaplatin-induced neuropathy via Gi protein-coupled receptors in the monoaminergic descending pain inhibitory system. Life Sci. 2014, 98, 49–54. [CrossRef]
55. Hache, G.; Guiard, B.P.; Nguyen, T.H.; Quesseveur, G.; Gardier, A.M.; Peters, D.; Munro, G.; Coudere, F. Antinociceptive activity of the new triple reuptake inhibitor NS18283 in a mouse model of chemotherapy-induced neuropathic pain. Eur. J. Pain 2015, 19, 322–333. [CrossRef] [PubMed]
56. Andoh, T.; Sakamoto, A.; Kuraishi, Y. Effects of xaliproden, a 5-HT(1)A agonist, on mechanical allodynia caused by chemotherapeutic agents in mice. Gastroenterology 2000, 118, 1197–1207. [CrossRef]
57. Hoyer, D.; Clarke, D.E.; Fozard, J.R.; Hartig, P.R.; Martin, G.R.; Mylecharane, E.J.; Saxena, P.R.; Humphrey, P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 1994, 46, 157–203.
58. Hershman, D.L.; Lacchetti, C.; Dworkin, R.H.; Lavoie Smith, E.M.; Bleeker, J.; Cavaletti, G.; Chauhan, C.; Gavin, P.; Lustberg, M.B. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 2014, 32, 1941–1967. [CrossRef] [PubMed]
59. Ward, S.J.; McAllister, S.D.; Kawamura, R.; Murase, R.; Neelakantan, H.; Walker, E.A. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy. Br. J. Pharmacol. 2014, 171, 636–645. [CrossRef] [PubMed]
60. Wang, Y.-Y.; Wei, Y.-Y.; Huang, J.; Wang, W.; Tamamaki, N.; Li, Y.-Q.; Wu, S.-X. Expression patterns of 5-HT receptor subtypes 1A and 2A on GABAergic neurons within the spinal dorsal horn of GAD67-GFP knock-in mice. J. Chem. Neuroanat. 2009, 38, 75–81. [CrossRef] [PubMed]
61. Zhuo, M. Molecular mechanisms of pain in the anterior cingulate cortex. Nat. Rev. Neurosci. 2005, 6, 533–544. [CrossRef]
62. Li, Y.; Hao, Y.; Zhu, J.; OwYang, C. Serotonin released from intestinal enterochromaffin cells mediates luminal non–cholecystokinin-stimulated pancreatic secretion in rats. Am. J. Physiol. 2006, 290, G310–G318. [CrossRef] [PubMed]
63. Peng, Y.B.; Lin, Q.; Willis, W.D. The role of 5-HT3 receptors in periaqueductal gray-induced inhibition of nociceptive dorsal horn neurons in rats. J. Pharmacol. Exp. Ther. 2000, 292, 671–680. [CrossRef] [PubMed]
77. Oyama, T.; Ueda, M.; Kuraishi, Y.; Akaike, A.; Satoh, M. Dual effect of serotonin on formalin-induced nociception in the rat spinal cord. *Neurosci. Res.* **1996**, *25*, 129–135. [CrossRef]

78. Zhang, Y.-Q.; Gao, X.; Ji, G.-C.; Huang, Y.-L.; Wu, G.-C.; Zhao, Z.-Q. Expression of 5-HT1A receptor mRNA in rat lumbar spinal dorsal horn neurons after peripheral inflammation. *Pain* **2002**, *98*, 287–295. [CrossRef]

79. Todorovic, S.; Anderson, E.G. Serotonin preferentially hyperpolarizes capsaicin-sensitive C type sensory neurons by activating 5-HT1A receptors. *Brain Res.* **1992**, *585*, 212–218. [CrossRef]

80. Domocos, D.; Selescu, T.; Ceafalan, L.C.; Iodi Carstens, M.; Carstens, E.; Babes, A. Role of 5-HT1A and 5-HT3 receptors in serotonergic activation of sensory neurons in relation to itch and pain behavior in the rat. *J. Neurosci. Res.* **2020**, *98*, 1999–2017. [CrossRef]

81. Hénon, A.; Dubayle, D. A focus on mast cells and pain. *J. Neuroimmunol.* **2013**, *264*, 1–7. [CrossRef]

82. Sakamoto, A.; Andoh, T.; Kuraishi, Y. Involvement of mast cells and proteinase-activated receptor 2 in oxaliplatin-induced mechanical allodynia in mice. *Pharmacol. Res.* **2016**, *105*, 84–92. [CrossRef] [PubMed]

83. Laporte, A.; Doyen, C.; Nevo, I.; Chauveau, J.; Hauw, J.; Hamon, M. Autoradiographic mapping of serotonin 5-HT1A, 5-HT1D, 5-HT2A and 5-HT3 receptors in the aged human spinal cord. *J. Chem. Neuroanat.* **1996**, *11*, 67–75. [CrossRef]

84. Marlier, L.; Teilhac, J.-R.; Cerruti, C.; Privat, A. Autoradiographic mapping of 5-HT1, 5-HT1A, 5-HT1B and 5-HT2 receptors in the rat spinal cord. *Brain Res.* **1991**, *550*, 15–23. [CrossRef]

85. Leysen, J. 5-HT2 receptors. *Curr. Drug Targets CNS Neurol. Disord.* **2004**, *3*, 11–26. [CrossRef] [PubMed]

86. Xie, H.; Dong, Z.-Q.; Ma, F.; Bauer, W.R.; Wang, X.; Wu, G.-C. Involvement of serotonin 2A receptors in the analgesic effect of tramadol in mono-arthritis rats. *Brain Res.* **2008**, *1210*, 76–83. [CrossRef] [PubMed]

87. Pichon, X.; Wattiez, A.S.; Becamel, C.; Ehrlich, I.; Bockaert, J.; Eschaler, A.; Marin, P.; Courteix, C. Disrupting 5-HT2A receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic pain. *Mol. Ther.* **2010**, *18*, 1462–1470. [CrossRef]

88. Dupuis, A.; Wattiez, A.-S.; Pinguet, J.; Richard, D.; Libert, F.; Chalus, M.; Aissouni, Y.; Sion, B.; Ardid, D.; Marin, P. Increasing spinal 5-HT2A receptor responsiveness mediates anti-allodynic effect and potentiates fluoxetine efficacy in neuropathic rats. Evidence for GABA release. *Pharmacol. Res.* **2017**, *118*, 93–103. [CrossRef]

89. Sánchez-Brulla, I.; Boulanguez, P.; Brocard, C.; Liabeuf, S.; Viallat-Lieutaud, A.; Navarro, X.; Udina, E.; Brocard, F. Activation of 5-HT2A receptors restores KCC2 function and reduces neuropathic pain after spinal cord injury. *Neuroscience* **2018**, *387*, 48–57. [CrossRef]

90. Silveira, J.W.S.; Dias, Q.M.; Del Bel, E.A.; Prado, W.A. Serotonin receptors are involved in the spinal mediation of descending facilitation of surgical incision-induced increase of Fos-like immunoreactivity in neuropathic rats. Evidence for GABA release. *Pharmacol. Res.* **2017**, *118*, 93–103. [CrossRef]

91. Tavares, L.R.R.; Baptista-de Souza, D.; Canto-de Souza, A. Activation of 5-HT2C (but not 5-HT1A) receptors in the amygdala enhances fear-induced antinociception: Blockade with local 5-HT2C antagonist or systemic fluoxetine. *Neuropharmacology* **2018**, *135*, 376–385. [CrossRef]

92. Baptista, D.; Nunes-de Souza, R.L.; Canto-de Souza, A. Activation of 5-HT2C receptors in the dorsal periaqueductal gray increases antinociception in mice exposed to the elevated plus-maze. *Behav. Brain Res.* **2012**, *235*, 42–47. [CrossRef]

93. Hannon, J.; Hoyer, D. Molecular biology of 5-HT receptors. *Behav. Brain Res.* **2008**, *195*, 198–213. [CrossRef]

94. Conte, D.; Legg, E.; McCourt, A.; Silajdzic, E.; Nagy, G.; Maxwell, D. Transmitter content, origins and connections of axons in the spinal cord that possess the serotonin (5-hydroxytryptamine) 3 receptor. *Neuroscience* **2005**, *134*, 165–173. [CrossRef] [PubMed]

95. Lang, P.M.; Moalem-Taylor, G.; Tracey, D.J.; Bostock, H.; Grafe, P. Activity-dependent modulation of axonal excitability in unmyelinated peripheral rat nerve fibers by the 5-HT (3) serotonin receptor. *J. Neurophysiol.* **2006**, *96*, 2963–2971. [CrossRef]

96. Giordano, J.; Dyche, J. Differential analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse. *Neuropharmacology* **1989**, *28*, 423–427. [CrossRef]

97. Woolley, M.L.; Marsden, C.A.; Fone, K.C. 5-hitz receptors. *Curr. Drug Targets CNS Neurol. Disord.* **2004**, *3*, 59–79. [CrossRef] [PubMed]

98. Pineda-Farias, J.B.; Barragán-Iglesias, P.; Valdivieso-Sánchez, A.; Rodriguez-Silverio, J.; Flores-Murrieta, F.J.; Granados-Soto, V.; Rocha-González, H.I. Spinal 5-HT4 and 5-HT6 receptors contribute to the maintenance of neuropathic pain in rats. *Pharmacol. Rep.* **2017**, *69*, 916–923. [CrossRef]

99. Castañeda-Corral, G.; Rocha-Gonzalez, H.I.; Araiza-Saldana, C.; Ambriz-Tututi, M.; Vidal-Cantú, G.; Granados-Soto, V. Role of peripheral and spinal 5-HT6 receptors according to the rat formalin test. *Neuroscience* **2009**, *162*, 444–452. [CrossRef] [PubMed]

100. Duan, Z.; Li, J.; Pang, X.; Wang, H.; Su, Z. Blocking mammalian target of rapamycin (mTOR) alleviates neuropathic pain induced by chemotherapeutic bortezomib. *Cell. Physiol. Biochem.* **2018**, *48*, 54–62. [CrossRef] [PubMed]

101. Sommer, C. Serotonin in pain and analgesia. *Mol. Neurobiol.* **2004**, *30*, 117–125. [CrossRef]

102. Le Bars, D. Serotonin and pain. *Neuronal Serotonin* **2018**, *171*, 226. [CrossRef]

103. Jacobs, S.; McCully, C.L.; Murphy, R.F.; Bacher, J.; Balis, F.M.; Fox, E. Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. *Cancer Chemother. Pharmacol.* **2010**, *65*, 817–824. [CrossRef] [PubMed]

104. Cavaletti, G. Peripheral neurotoxicity of platinum-based chemotherapy. *Nat. Rev. Cancer* **2008**, *8*, 72. [CrossRef]

105. Li, D.; Chung, G.; Kim, S.K. The Involvement of Central Noradrenergic Pathway in the Analgesic Effect of Bee Venom Acupuncture on Vincristine-Induced Peripheral Neuropathy in Rats. *Toxins* **2020**, *12*, 775. [CrossRef]
106. Dobson, C.; Tohyama, Y.; Diksic, M.; Hamel, E. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. *Cephalalgia* 2004, 24, 2–11. [CrossRef] [PubMed]

107. Huang, X.; Yang, J.; Yang, S.; Cao, S.; Qin, D.; Zhou, Y.; Li, X.; Ye, Y.; Wu, J. Role of tandospirone, a 5-HT1A receptor partial agonist, in the treatment of central nervous system disorders and the underlying mechanisms. *Oncotarget* 2017, 8, 102705. [CrossRef]

108. Nakai, K.; Nakae, A.; Oba, S.; Mashimo, T.; Ueda, K. 5-HT2C receptor agonists attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain. *Eur. J. Pain* 2010, 14, 999–1006. [CrossRef]

109. Obata, H.; Saito, S.; Sakurazawa, S.; Sasaki, M.; Usui, T.; Goto, F. Antiallodynic effects of intrathecally administered 5-HT2C receptor agonists in rats with nerve injury. *Pain* 2004, 108, 163–169. [CrossRef]

110. Nakae, A.; Nakai, K.; Tanaka, T.; Hosokawa, K.; Mashimo, T. Serotonin 2C receptor alternative splicing in a spinal cord injury model. *Neurosci. Lett.* 2013, 532, 49–54. [CrossRef]

111. Obata, H.; Saito, S.; Sasaki, M.; Ishizaki, K.; Goto, F. Antiallodynic effect of intrathecally administered 5-HT2 agonists in rats with nerve ligation. *Pain* 2001, 90, 173–179. [CrossRef]

112. Sasaki, M.; Ishizaki, K.; Obata, H.; Goto, F. Effects of 5-HT2 and 5-HT3 receptors on the modulation of nociceptive transmission in rat spinal cord according to the formalin test. *Eur. J. Pharmacol.* 2001, 424, 45–52. [CrossRef]

113. Cardenas, C.G.; Mar, L.P.; Scroggs, R.S. Two parallel signaling pathways couple 5HT1A receptors to N-and L-type calcium channels in C-like rat dorsal root ganglion cells. *J. Neurophysiol.* 1997, 77, 3284–3296. [CrossRef] [PubMed]

114. Millan, M.J. The induction of pain: An integrative review. *Prog. Neurobiol.* 1999, 57, 1–164. [CrossRef] [PubMed]

115. Cardenas, C.G.; Mar, L.P.; Vysokanov, A.V.; Arnold, P.B.; Cardenas, L.M.; Surmeier, D.J.; Scroggs, R.S. Serotonergic modulation of hyperpolarization-activated current in acutely isolated rat dorsal root ganglion neurons. *J. Physiol.* 1999, 518, 507–523. [CrossRef] [PubMed]

116. Millan, M.; Girardon, S.; Bervoets, K. 8-OH-DPAT-induced spontaneous tail-flicks in the rat are facilitated by the selective serotonin (5-HT) 2C agonist, RO 60-0175: Blockade of its actions by the novel 5-HT2C receptor antagonist SB 206,553. *Neuropharmacology* 1997, 36, 743–745. [CrossRef]

117. Kukushkin, M.; Igon‘kina, S. Role of 5-HT3 Receptors in the Mechanisms of Central Pain Syndrome. *Bull. Exp. Biol. Med.* 2003, 135, 552–555. [CrossRef]

118. Kawamata, T.; Omote, K.; Toriyabe, M.; Yamamoto, H.; Namiki, A. The activation of 5-HT3 receptors evokes GABA release in the spinal cord. *Brain Res.* 2003, 978, 250–255. [CrossRef]

119. McCleane, G.J.; Suzuki, R.; Dickenson, A.H. Does a single intravenous injection of the 5HT3 receptor antagonist ondansetron have an analgesic effect in neuropathic pain? A double-blinded, placebo-controlled cross-over study. *Anesth. Analg.* 2003, 97, 1474–1478. [CrossRef]

120. Chen, Y.; Oatway, M.A.; Weaver, L.C. Blockade of the 5-HT3 receptor for days causes sustained relief from mechanical allodynia following spinal cord injury. *J. Neurosci.* Res. 2009, 87, 418–424. [CrossRef]

121. Ye, J.H.; Mui, W.C.; Ren, J.; Hunt, T.E.; Wu, W.-H.; Zbuzek, V.K. Ondansetron exhibits the properties of a local anesthetic. *Anesth. Analg.* 1997, 85, 1116–1121. [CrossRef]

122. Kursheyev, Y.A.; Brown, A.M.; Wang, L.; Benedict, C.R.; Rampe, D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. *J. Pharmacol. Exp. Ther.* 2000, 295, 614–620. [PubMed]